Group 1 - The "2025 National Visual Health Science Popularization Action" was officially launched on June 5, 2025, with the theme "Technology Empowers Eye Health, Building a Bright New Future Together" [1] - The initiative aims to explore the latest practical achievements of new information technology in the field of eye health and to break the public's cognitive blind spots regarding new applications and devices through expert science popularization [1] - The event coincides with the 30th National "Eye Care Day," highlighting the establishment of a near-sighted prevention work system led by the government and involving multiple departments, schools, parents, and students [2] Group 2 - The National Market Supervision Administration has been advancing near-sighted prevention work through policy implementation, strict regulation, and public education, with plans to continue addressing market issues to support youth eye health [4] - The National Health Commission has established a comprehensive monitoring network and improved standards and guidelines to protect children's and adolescents' vision health, focusing on early intervention and scientific research [6] - Experts emphasized the importance of artificial intelligence in eye health, particularly in prevention, diagnosis, treatment, and education, showcasing its potential to enhance medical innovation [10] Group 3 - The event featured discussions on various eye health topics, including modern artificial lenses and dry eye treatment, highlighting advancements in technology and treatment methods [17] - The "People's Health 'Into Campus' Care Plan" was officially launched during the event, aiming to integrate resources for science education in schools and enhance youth health literacy [19][21] - The initiative received professional guidance from several prestigious universities and hospitals, with support from various organizations in the eye care sector [20]

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-019 华厦眼科医院集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、股东大会届次：2024 年年度股东大会。 2、会议召开时间 （1）现场会议时间：2025 年 5 月 20 日下午 15:00； （2）网络投票时间：2025 年 5 月 20 日； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 20 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 20 日 9:15-15:00。 3、会议地点：厦门市湖里区五通西路 999 号 17 楼大会议室。 4、会议召开方式：本次股东大会采用现场投票与网络投票相结合的方式召 开。 （二）会议出席情况 1、通过现场和网络投票的股东 ...

上海市锦天城律师事务所 关于华厦眼科医院集团股份有限公司 2024 年年度股东大会的 法律意见书 致：华厦眼科医院集团股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受华厦眼科医院集团股份有 限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简 称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司股东会规则》等法律、法规、规章和其他规范性文件 以及《华厦眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，出具本法律意见书。 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于华厦眼科医院集团股份有限公司 2024 年年度股东大会的 法律意见书 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Huaxia Eye Hospital Group, noting its stock price increase and market capitalization [1] - As of May 20, the closing price of Huaxia Eye Hospital was 19.21 yuan, with a PE ratio of 38.20 times and a total market value of 16.136 billion yuan [1] - The average PE ratio for the medical services industry is 38.49 times, with a median of 39.26 times, placing Huaxia Eye Hospital at the 28th position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, 18 institutions held shares in Huaxia Eye Hospital, including 10 funds, with a total holding of 192.8128 million shares valued at 3.843 billion yuan [1] - The main business of Huaxia Eye Hospital includes specialized ophthalmic medical services, focusing on cataract projects, posterior segment projects, refractive projects, and comprehensive optometry projects [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 1.093 billion yuan, a year-on-year increase of 11.74%, and a net profit of 150 million yuan, reflecting a year-on-year decrease of 4.00%, with a gross profit margin of 44.97% [1]

投资者关系活动记录表 编号：2025-003 | | □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 | | --- | --- | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及人员 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与 | | 姓名 | 厦门辖区上市公司 2024 年年报业绩说明会暨投资者网上集体 | | | 接待日活动的投资者 | | 时间 | 2025 年 5 月 15 日（周四）下午 15:40~17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 陈凤国先生 董事 | | | 陈鹭燕女士 财务总监 | | 上市公司接待人员 姓名 | 曹乃恩先生 董事会秘书 | | | 王志强先生 独立董事 | | | 赵 冀先生 保荐代表人 | | | 1、请问一下 年公司，持续发展和业务开展做了哪些调 25 | | | 整和创新？ | | | 尊敬的投资者您好，感谢您对华厦眼科的关注。从 2025 | | | 年起，公司将按照《华 ...

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Huaxia Eye Hospital Group, noting its recent stock price increase and market position within the healthcare sector [1][2] - As of May 12, Huaxia Eye Hospital's closing price was 19.35 yuan, with a PE ratio of 38.48, marking a new low in 24 days and a total market capitalization of 16.254 billion yuan [1] - The company ranks 30th in the medical services industry, which has an average PE ratio of 38.15 and a median of 38.48 [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Huaxia Eye Hospital achieved a revenue of 1.093 billion yuan, representing a year-on-year increase of 11.74%, while net profit was 150 million yuan, reflecting a year-on-year decrease of 4% [1] - The company's gross profit margin stands at 44.97% [1] - In terms of capital flow, on May 12, the net inflow of main funds into Huaxia Eye Hospital was 6.9774 million yuan, with a total inflow of 7.664 million yuan over the past five days [1]